W e appreciate the interest in our review of antibiotic duration in hospitalized patients. Drs. Sikkens and van Agtmael comment that drug pharmacokinetics can alter true treatment duration.
1,2 Specifically, azithromycin has a long half-life in tissues. 3 We did not consider pharmacokinetics in our prespecified protocol for study inclusion, nor require that studies compare the same drug between treatment groups. This is consistent with a systematic review of antibiotic duration in community-acquired pneumonia, which included 3 of the 4 studies comparing shortcourse azithromycin to a longer course of another antibiotic. 4 Similarly, in a recent pilot study of antibiotic duration in bloodstream infections, only treatment duration was prespecified. 5 We agree that the differing pharmacokinetics between drugs is a limitation to our findings.
To assess whether the inclusion of studies using short-course azithromycin biased our conclusions, we performed an additional meta-analysis for clinical efficacy excluding the 4 studies that compared azithromycin with another drug. This subgroup included 9 trials comprising 1270 patients. The overall risk difference was 0.3% (95% CI −2.7%, 3.3%), consistent with the primary findings that short-course antibiotic treatment is non-inferior to long-course antibiotic treatment. None of these 4 studies examined mortality; thus, the meta-analyses for shortterm and long-term mortality are unaffected. 
